SCHEMBL275698

SCHEMBL275698

Cc1nn(C)c(C)c1Oc1ccc(Br)cc1C=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.41
NMT1 P30419 3/20 0.39
CASP3 P42574 1/20 0.38
FPR2 P25090 1/20 0.38
PROKR1 Q8TCW9 1/20 0.38
LMNA P02545 2/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
ERN1 O75460 2/20 0.36
SMN1; SMN2 Q16637 3/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PLK1 P53350 1/20 0.35
PLK3 Q9H4B4 1/20 0.35
PLK2 Q9NYY3 1/20 0.35
NR2F2 P24468 1/20 0.34
CRHBP P24387 1/20 0.34
CRHR2 Q13324 1/20 0.34
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
AMY1A P0DUB6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12438307 0.84 SMN1; SMN2 (0.33) NMT1LMNASMN1; SMN2CYP2C9CYP2C19
SCHEMBL275898 0.84 ERN1 (0.36) NMT1LMNAERN1SMN1; SMN2CYP2C9
SCHEMBL278924 0.77 LMNA (0.35) NMT1CASP3FPR2PROKR1LMNA
SCHEMBL276112 0.71 PTGDR2 (0.46) PTGDR2LMNATSHRMAPK1ERN1
SCHEMBL153974 0.68 ERN1 (0.58) PTGDR2LMNATSHRERN1SMN1; SMN2
SCHEMBL29890082 0.68 ERN1 (0.58) PTGDR2LMNATSHRERN1SMN1; SMN2
SCHEMBL276011 0.68 PTGDR2 (0.46) PTGDR2LMNATSHRMAPK1ERN1
SCHEMBL2657727 0.68 HTT (0.38) NMT1LMNATSHRMAPK1NR2F2
SCHEMBL275629 0.67 LMNA (0.61) PTGDR2LMNATSHRMAPK1ERN1
SCHEMBL21371124 0.67 NPSR1 (0.51) PTGDR2LMNAMAPK1ERN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
EP-2229396-B1 SPIROINDOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-10 EP disclosed
EP-2229396-A1 SPIROINDOLINONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-22 EP disclosed
WO-2009077357-A1 SPIROINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 WO disclosed
WO-2009077357-A1 SPIROINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 WO disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156610-A1 Spiroindolinone Derivatives SDHA, AR, XPOT PTGDR2 996/4885NMT1 3607/4885CASP3 208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.